Jianmin Group

Jianmin Group (健民集团) is a Chinese pharmaceutical enterprise headquartered in Wuhan, Hubei Province. The company is primarily engaged in the research, development, production, and sale of traditional Chinese medicine (TCM) products, health supplements, and related pharmaceutical goods. It is listed on the Shanghai Stock Exchange under the ticker 600976. The group traces its roots to the historic 'Ye Kaitai' pharmacy brand, a well-known TCM pharmacy in Wuhan with a heritage spanning several centuries. Over time, the business evolved into a modern pharmaceutical corporation. Its flagship product, Longmu Zhuanggu Granules (龙牡壮骨颗粒), is a pediatric calcium supplement and TCM formula that has become a household name in China for supporting children's bone health. Jianmin Group operates across the pharmaceutical value chain, including manufacturing, distribution, and retail pharmacy chains. Its product portfolio covers pediatric medicines, gynecological and obstetric products, orthopedic and health supplements, and general TCM preparations. The company markets its products primarily in China, leveraging both traditional pharmacy channels and modern retail and hospital networks. As a publicly traded company, Jianmin Group is subject to the disclosure and governance requirements of the Shanghai Stock Exchange. The company continues to invest in brand building, product innovation, and the modernization of TCM production, aligning with broader national policies that support the development of the traditional medicine industry.

Jianmin Group's origins are linked to the historic 'Ye Kaitai' (叶开泰) pharmacy, a renowned traditional Chinese medicine establishment founded in Wuhan during the Ming dynasty. The Ye Kaitai brand built a reputation over centuries for its quality TCM preparations and became one of the most recognized pharmacy names in central China. In the 20th century, the business underwent restructuring and was eventually reorganized into a modern pharmaceutical enterprise. The company adopted the name 'Jianmin' (健民), which conveys the idea of 'strengthening the people' or 'health for the people,' reflecting its focus on public health through traditional medicine. During the latter half of the 20th century, Jianmin Group expanded its manufacturing capabilities and developed a portfolio of proprietary TCM products. A major milestone was the development and launch of Longmu Zhuanggu Granules, a pediatric calcium and bone-health supplement that combined traditional Chinese medicinal ingredients with modern nutritional science. The product became widely popular and remains the company's flagship offering. In the 1990s and 2000s, Jianmin Group pursued a path of corporatization and public listing. The company was listed on the Shanghai Stock Exchange, enabling it to raise capital for expansion, research and development, and brand building. It also diversified into pharmaceutical distribution and retail pharmacy operations, strengthening its presence across the value chain. In recent years, Jianmin Group has continued to invest in modernizing its production facilities to meet contemporary Good Manufacturing Practice (GMP) standards, while promoting the legacy of TCM. The company has also engaged in brand rejuvenation efforts to appeal to younger consumers and to expand its presence in the health supplement market. Its operations remain primarily focused on the Chinese domestic market, where demand for TCM and pediatric health products continues to grow.

• Historic 'Ye Kaitai' pharmacy founded in Wuhan, laying the heritage foundation for Jianmin Group.

• Business reorganized into a modern pharmaceutical enterprise under the Jianmin name.

• Launch of Longmu Zhuanggu Granules, which became the company's flagship pediatric product.

• Listed on the Shanghai Stock Exchange (ticker 600976).

• Longmu Zhuanggu Granules

  A pediatric calcium and bone-health supplement combining TCM ingredients, widely recognized in China.

• Pediatric TCM medicines

  A range of traditional Chinese medicine products for children's common ailments.

• Gynecological and obstetric medicines

  TCM-based products for women's health.

• Health supplements

  Dietary and health supplements marketed under the Jianmin brand.

• 2018

  One batch of Xiaojin capsules fails microbial limit test, emergency recall

  In July 2018, Jianmin Group disclosed that one of nearly 50 sampled batches of Xiaojin capsules failed the microbial limit test and was urgently recalled. The company preliminarily attributed the failure to localized contamination possibly caused by improper transport, and the explanation remained preliminary.

  Source

Read more

1. 1Jianmin Group official websitejmzy.com
2. 2One batch of Xiaojin capsules fails microbial limit test, emergency recallnbd.com.cn